Adimab has expanded its research collaborations with Merck and Lilly. The new agreement provides Merck with expanded access to its technology to identify human antibody candidates, including potentially bispecific antibody candidates across all disease areas. Adimab will discover therapeutic antibody candidates to multiple targets selected by Merck for a three-year period. Adimab will receive upfront payments and is eligible to receive preclinical and clinical development milestones, as well as royalties on product sales.
Additionally, Adimab has expanded its research agreement with Lilly to include the discovery and optimization of multiple bispecific antibodies targeting molecular targets identified by Lilly.
“We are always pleased when our existing partners choose to expand their relationship with us,” said Tillman Gerngross, Adimab’s chief executive officer and co-founder. “The antibody discovery arena has become very competitive and nothing is more validating than existing partners coming back for broader access to our platform.”
Adimab Expands Collaborations with Merck and Lilly
Published January 8, 2013
blog comments powered by Disqus